Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 14/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 14/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 14/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 14/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269972 | 0.94 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1819998 | 0.94 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1819999 | 0.94 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6651150 | 0.85 | — | — | |
| SCHEMBL26928055 | 0.82 | CHRM2 (0.57) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11820231 | 0.82 | CHRM2 (0.57) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11451025 | 0.81 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4630395 | 0.80 | DPP7 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4341298 | 0.77 | ALDH1A1 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL25095482 | 0.76 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CHRM2 483/4885CHRM4 860/4885CHRM5 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.